Sacheerome H1 FY27 revenue ₹84.48 Cr; YEIDA facility begins trial production
Sacheerome · Chemicals & Petrochemicals
What the filing says
- H1 FY27 revenue was ₹84.48 Cr, with YoY growth of 10.34%; the filing says figures are management estimates subject to final audit adjustments.
- Installation and commissioning of the new YEIDA facility is complete, and trial production began in September 2026.
- As on September 30, 2026: annual production capacity 27,60,000 kg, 60 R&D specialists, 2 manufacturing units. The YEIDA facility will house R&D, Quality Control, Application and Consumer Evaluation Centres.
Why it's rated notable: amount is a tenth or more of annual revenue
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
General Updates
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sacheerome
- Capex / expansionNotableSacheerome Limited begins trial production at new manufacturing plant in U.P.
Other capex / expansion filings this fortnight
- Capex / expansionTinna Rubber & Infrastructure LtdTinna Rubber reports record H1 FY27 profit with 50% EBITDA growth YoY
- Capex / expansionPitti Engg.Pitti Engineering approves ₹450 crore capex for capacity expansion and consolidation
- Capex / expansionPitti Engg.Pitti Engineering reports Q2 & H1 FY27 results, announces ₹450 crore capex for expansion
- Capex / expansionNuvoco VistasNuvoco Vistas reports Q2 FY27 results with 13.5% revenue growth and capacity expansion
- Capex / expansionHindustan Petroleum Corporation LtdHindustan Petroleum Corporation Limited reports Q2 and H1 FY27 financial results
- PC Jeweller reports Q2FY27 results with 28% revenue growth and debt-free status
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.